Saxagliptin, a DPP-4 inhibitor, prolongs the action of GLP-1, resulting in the reversal of cognitive deficits associated with reduced amyloid load, tau protein phosphorylation, and brain inflammation, as demonstrated by Kosaraju J. et al. (2013) [200]. The gene discussed is DPP4; the disease is Cognitive impairment.